These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 35278509)

  • 1. Drug delivery of sofosbuvir drug capsulated with the β-cyclodextrin basket loaded on chitosan nanoparticle surface for anti-hepatitis C virus (HCV).
    El-Shafai NM; Masoud MS; Ibrahim MM; Ramadan MS; Mersal GAM; El-Mehasseb IM
    Int J Biol Macromol; 2022 May; 207():402-413. PubMed ID: 35278509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spectroscopic study to verify the anti-hepatitis C virus (HCV) treatment through a delivery system of the sofosbuvir drug on chitosan and pycnogenol nanoparticles surface.
    El-Shafai NM; Nada AI; Farrag MA; Alatawi K; Alalawy AI; Al-Qahtani SD; El-Mehasseb IM
    Spectrochim Acta A Mol Biomol Spectrosc; 2023 Dec; 302():123063. PubMed ID: 37390719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spectroscopic study of self-assembly of anti-hepatitis C virus sofosbuvir drug with bio-polymeric nanoparticles for improving the drug release effect.
    Shawky S; El-Shafai NM; El-Mehasseb IM; Shoueir KR; El-Kemary MA
    Spectrochim Acta A Mol Biomol Spectrosc; 2021 Nov; 261():120008. PubMed ID: 34087770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sandwich nanohybrid of chitosan-polyvinyl alcohol for water treatment and Sofosbuvir drug delivery for anti-hepatitis C virus (HCV).
    El-Shafai NM; Shawky S; El-Mehasseb IM; El-Kemary MA
    Int J Biol Macromol; 2021 Nov; 190():927-939. PubMed ID: 34480910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.
    Ciesek S; Proske V; Otto B; Pischke S; Costa R; Lüthgehetmann M; Polywka S; Klempnauer J; Nashan B; Manns MP; von Hahn T; Lohse AW; Wedemeyer H; Mix H; Sterneck M
    Transpl Infect Dis; 2016 Jun; 18(3):326-32. PubMed ID: 26988272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mathematical modelling of the transport of hydroxypropyl-β-cyclodextrin inclusion complexes of ranitidine hydrochloride and furosemide loaded chitosan nanoparticles across a Caco-2 cell monolayer.
    Sadighi A; Ostad SN; Rezayat SM; Foroutan M; Faramarzi MA; Dorkoosh FA
    Int J Pharm; 2012 Jan; 422(1-2):479-88. PubMed ID: 22101294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dramatic response of hepatitis C patients chronically infected with hepatitis C virus genotype 3 to sofosbuvir-based therapies in Punjab, Pakistan: A prospective study.
    Iqbal S; Yousuf MH; Yousaf MI
    World J Gastroenterol; 2017 Nov; 23(44):7899-7905. PubMed ID: 29209131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The enzyme-sensitive release of prodigiosin grafted β-cyclodextrin and chitosan magnetic nanoparticles as an anticancer drug delivery system: Synthesis, characterization and cytotoxicity studies.
    Rastegari B; Karbalaei-Heidari HR; Zeinali S; Sheardown H
    Colloids Surf B Biointerfaces; 2017 Oct; 158():589-601. PubMed ID: 28750341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro drug release of natamycin from β-cyclodextrin and 2-hydroxypropyl-β-cyclodextrin-functionalized contact lens materials.
    Phan CM; Subbaraman LN; Jones L
    J Biomater Sci Polym Ed; 2014; 25(17):1907-19. PubMed ID: 25226305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The preparation, characterization, and pharmacokinetic studies of chitosan nanoparticles loaded with paclitaxel/dimethyl-β-cyclodextrin inclusion complexes.
    Ye YJ; Wang Y; Lou KY; Chen YZ; Chen R; Gao F
    Int J Nanomedicine; 2015; 10():4309-19. PubMed ID: 26170666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.
    Aqel B; Leise M; Vargas HE; Watt KD; Keaveny AP; Zhang N; Zhang N; Pungpapong S
    Ann Hepatol; 2018 Aug; 17(5):815-821. PubMed ID: 30145562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing direct acting antivirals for hepatitis C using observational data - Why and how?
    Young J; Wong S; Janjua NZ; Klein MB
    Pharmacol Res Perspect; 2020 Oct; 8(5):e00650. PubMed ID: 32894643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.
    Wu DB; Jiang W; Wang YH; Chen B; Wang ML; Tao YC; Chen EQ; Tang H
    J Viral Hepat; 2019 Mar; 26(3):316-322. PubMed ID: 30380166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
    Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
    J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Permeability Profiles and Intestinal Toxicity Assessment of Hydrochlorothiazide and Its Inclusion Complex with β-Cyclodextrin Loaded into Chitosan Nanoparticles.
    Onnainty R; Schenfeld EM; Petiti JP; Longhi MR; Torres A; Quevedo MA; Granero GE
    Mol Pharm; 2016 Nov; 13(11):3736-3746. PubMed ID: 27756134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.
    Gane EJ; Stedman CA; Hyland RH; Ding X; Svarovskaia E; Subramanian GM; Symonds WT; McHutchison JG; Pang PS
    Gastroenterology; 2014 Mar; 146(3):736-743.e1. PubMed ID: 24262278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
    J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
    Mizokami M; Dvory-Sobol H; Izumi N; Nishiguchi S; Doehle B; Svarovskaia ES; De-Oertel S; Knox S; Brainard DM; Miller MD; Mo H; Sakamoto N; Takehara T; Omata M
    J Viral Hepat; 2016 Oct; 23(10):780-8. PubMed ID: 27196675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A real-world study of sofosbuvir-based drug treatment for hepatitis C virus genotype 6 infection in Hainan region of China].
    Wang J; Liu M; Zhang YR; Xing HY; Li H; Lin F; Wu T
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):679-684. PubMed ID: 34371539
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
    Tao T; Jiang X; Chen Y; Song Y
    Int J Infect Dis; 2017 Feb; 55():56-71. PubMed ID: 28040553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.